TK IMPACT: Treatment Monitoring of Hormone Receptor Positive (HR+), HER2 Negative (HER2-) Metastatic Breast Cancer (MBC) Patients Receiving CDK 4/6 Inhibitors (CDK4/6i) with DiviTum® Thymidine Kinase 1 Activity

被引：1
|
作者：
Bagegni, Nusayba A.
Grigsby, Isabella
Nehring, Leslie
Luo, Jingqin
Carson, Jennifer Powers
Gibson, David W.
Horvath, Meghan
Clifton, Katherine K.
Ademuyiwa, Foluso O.
Suresh, Rama
Frith, Ashley
Davis, Andrew A.
Peterson, Lindsay L.
Bose, Ron
Williams, Amy
Bergqvist, Mattias
Ma, Cynthia
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-OT3-11-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT3-11-01
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Immune effects of CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer: Relief from immunosuppression is associated with clinical response
    Scirocchi, Fabio
    Scagnoli, Simone
    Botticelli, Andrea
    Di Filippo, Alessandra
    Napoletano, Chiara
    Zizzari, Ilaria Grazia
    Strigari, Lidia
    Tomao, Silverio
    Cortesi, Enrico
    Rughetti, Aurelia
    Marchetti, Paolo
    Nuti, Marianna
    EBIOMEDICINE, 2022, 79
  • [42] Patient & oncologist preferences for adjuvant CDK4/6i therapy in HR+/HER2-early breast cancer
    Beusterien, K.
    Law, E. H.
    Hallissey, B.
    Smith, M. L.
    Gaschler, M.
    Maculaitis, M. C.
    ANNALS OF ONCOLOGY, 2020, 31 : S321 - S322
  • [43] CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease
    Matutino, Adriana
    Amaro, Carla
    Verma, Sunil
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
  • [44] Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2-metastatic breast cancer
    Zagami, Paola
    Esposito, Angela
    Salimbeni, Beatrice Taurelli
    Giachetti, Pier Paolo Maria Berton
    Scafetta, Roberta
    Lambertini, Matteo
    Di Maio, Massimo
    Curigliano, Giuseppe
    Criscitiello, Carmen
    Cinieri, Saverio
    BREAST, 2025, 79
  • [45] Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2-advanced breast cancer
    Corona, Silvia Paola
    Generali, Daniele
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 321 - 330
  • [46] A phase I/IIb study of palbociclib (PALBO) plus everolimus (EVE) and exemestane (EXE) in hormone-receptor positive (HR+)/HER2-metastatic breast cancer (MBC) after progression on a CDK4/6 inhibitor (CDK4/6i): Results of the phase II study
    Barroso-Sousa, Romualdo
    Li, Tianyu
    Trippa, Lorenzo
    Rees, Rebecca
    Andrews, Chelsea
    Ferreira, Arlindo R.
    Helvie, Karla
    Partridge, Ann H.
    Overmoyer, Beth
    Winer, Eric P.
    Wagle, Nikhil
    Tolaney, Sara M.
    CANCER RESEARCH, 2020, 80 (04)
  • [47] First-in-human phase 1A study of RGT-419B, a next generation CDK4 inhibitor, in patients (pts) with hormone receptor positive (HR+) HER2advanced/metastatic breast cancer (ABC) who progressed on prior CDK4/6 inhibitors (CDK4/6i)
    Wander, Seth
    Valacer, Dave
    Zuniga, Richard
    Yeckes-Rodin, Heather
    Perkins, Christopher
    Ge, Lisa
    Yao, Lili
    Lin, Jing
    Begley, Dawn
    Sun, Feifei
    Zheng, Andie
    Han, Jing
    Xie, Zhi
    Bardia, Aditya
    Kalinsky, Kevin
    CANCER RESEARCH, 2024, 84 (09)
  • [48] Mutational signature analysis reveals patterns of genomic instability linked to resistance to endocrine therapy (ET) +/- CDK 4/6 inhibition (CDK4/6i) in estrogen receptor-positive/HER2-negative (ER+/HER2-) metastatic breast cancer (MBC)
    Marra, A.
    Gazzo, A.
    Gupta, A.
    Selenica, P.
    Da Silva, E. M.
    Pareja, F.
    Pei, X.
    Zhu, Y.
    Razavi, P.
    Safonov, A.
    Ferraro, E.
    Harris, R.
    Riaz, N.
    Reis-Filho, J. S.
    Chandarlapaty, S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S632 - S632
  • [49] How to Treat HR+/HER2-Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story
    Cogliati, Viola
    Capici, Serena
    Pepe, Francesca Fulvia
    di Mauro, Pierluigi
    Riva, Francesca
    Cicchiello, Federica
    Maggioni, Claudia
    Cordani, Nicoletta
    Cerrito, Maria Grazia
    Cazzaniga, Marina Elena
    LIFE-BASEL, 2022, 12 (03):
  • [50] Combination therapy with the AKT inhibitor, ipatasertib, endocrine therapy, and a CDK4/6 inhibitor for hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC): results from the phase I TAKTIC trial
    Wander, Seth A.
    Keenan, Jennifer C.
    Niemierko, Andrzej
    Juric, Dejan
    Spring, Laura M.
    Supko, Jeffrey
    Vidula, Neelima
    Isakoff, Steven J.
    Ryan, Lianne
    Padden, Sarah
    Fisher, Elizabeth
    Newton, Amber
    Moy, Beverly
    Ellisen, Leif
    Micalizzi, Douglas S.
    Bardia, Aditya
    CANCER RESEARCH, 2023, 83 (05)
12345